Trelegy ellipta 100-62.5-25 60S
Ended Awarded
- Contract number
- SPE2DB26FJRWW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $7,279
Award facts
- Contract value 100% obligated
- $7,278.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $7,278.84 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of TRELEGY ELLIPTA 100-62.5-25 (60-count units). The award, issued on October 28, 2025, with an ultimate completion date of October 29, 2025, carries no set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected as the awardee based on its established performance as a critical pharmaceutical supplier within the federal military medical supply chain and its registration in the System for Award Management since 2001.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, designated contract SPE2DR with a $499.99 billion ceiling value, was awarded on November 13, 2025, and authorizes DLA to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare operations globally. The contract structure positions DMS Pharmaceutical Group as a regional prime vendor contractor serving military healthcare facilities worldwide through a 30-month base period with three 30-month option periods extending through December 31, 2036.
Quick answers
Who was awarded contract SPE2DB26FJRWW?
SPE2DB26FJRWW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DB26FJRWW worth?
The government has obligated $7,279 on SPE2DB26FJRWW.
Is contract SPE2DB26FJRWW an order under another contract?
Yes. SPE2DB26FJRWW is a delivery order under SPE2DB24D9803, an indefinite delivery contract.
Was contract SPE2DB26FJRWW competed?
The extent of competition for SPE2DB26FJRWW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award